Indeed, its results increased in fatty liver disease associated with obesity in both animal and human models and the inhibition/knockdown of PPARγ ameliorates fatty liver in obese and NAFLD conditions [158,159]. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.